ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHVN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, and the lead plaintiff deadline is September 12, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated claims about the drug's prospects likely had a significant negative impact on Biohaven's business and financial condition [4] - The lawsuit asserts that once the true details were revealed, investors suffered damages due to the misleading public statements [4]